Products for Research Use Only
RegisterLogin

Nadifloxacin

CAT: 0804-HY-B0506-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0506-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8) . Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo[1][2][3][4][5].
CAS Number
124858-35-1
Product Name Alternative
OPC7251
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Antibiotic; Bacterial; DNA/RNA Synthesis; Interleukin Related
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/nadifloxacin.html
Purity
99.93
Solubility
DMSO : 25 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL
Smiles
O=C(C1=CN2C(C)CCC3=C2C(C1=O)=CC(F)=C3N4CCC(O)CC4)O
Molecular Formula
C19H21FN2O4
Molecular Weight
360.38
Precautions
H302, H315, H319, H335
References & Citations
[1]Jacobs, M.R. and P.C. Appelbaum, Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother, 2006. 7 (14) : p. 1957-66.|[2]Choudhury, S., et al., Efficacy and safety of topical nadifloxacin and benzoyl peroxide versus clindamycin and benzoyl peroxide in acne vulgaris: A randomized controlled trial. Indian J Pharmacol, 2011. 43 (6) : p. 628-31.|[3]Vogt K, et al. Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11 (10) : 943-945. |[4]Kuwahara K, et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci. 2005 Apr;38 (1) :47-55. |[5]Yamakawa T, et al. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49 (3) :455-65.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
IL-1; IL-6; IL-8; Quinolone

Alternative Products

CatalogName
N062-250MGNadifloxacin

Popular Products